Compare BIO-TECHNE Corp (TECH) vs Veralto Corp Common Stock (VLTO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Veralto Corp Common Stock — how do they compare? BIO-TECHNE Corp trades at $72.69 (market cap $11.37B), while Veralto Corp Common Stock trades at $101.5 (market cap $24.54B). The key difference: Veralto Corp Common Stock is far larger — about 2.2× BIO-TECHNE Corp's market cap, and Veralto Corp Common Stock pays the higher dividend (0.52%). Which is the better fit depends on your goals — on Pluang, investors hold BIO-TECHNE Corp for 64 Days and Veralto Corp Common Stock for 0 Days on average.
| TECH | VLTO | |
|---|---|---|
Market Cap | $11.37B | $24.54B |
Volume | 1,544,768 | 1,804,688 |
Sector | Health | Industrials |
52-Week High | $72.61 | $104.87 |
52-Week Low | $43.31 | $82.23 |
Typical Hold Time | 64 Days | 0 Days |
Enterprise Value | $11.40B | $25.80B |
Dividend Yield | 0.44% | 0.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.48, down 0.11% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average support. Recent earnings have been mixed, with Q2 2026 beating expectations but Q1 2026 missing. The company's pending acquisition by Merck KGaA for $73.00 per share, approved by shareholders (PRNewsWire, 2026-09-23), is a key near-term catalyst. Fundamentals indicate solid profitability with a 65.77% gross margin but elevated valuation ratios like a P/E of 62.52.
The outlook is dominated by the acquisition, offering a clear exit near the current price. Upside is capped by the deal price, while execution risks or regulatory hurdles pose downside. Analyst sentiment is neutral with a consensus hold rating. The stock presents a low-risk opportunity for merger arbitrage but limited growth potential for long-term investors absent competitive threats or integration challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Veralto Corp Common Stock
Veralto Corporation provides water quality and product quality technologies through two segments, Water Quality and Product Quality & Innovation. Its offerings include water analytics and treatment instruments, marking and coding equipment for packaging, and color measurement solutions such as X-Rite.
Read more on VLTO →
